Abstract:Thrombosis is a leading cause of death worldwide [1]. Recombinant tissue-type plasminogen activator (tPA) is the FDA-approved thrombolytic drug for ischemic strokes, myocardial infarction and pulmonary embolism. tPA is a multi-domain serine protease of the trypsin-family [2] and catalyses the critical step in fibrinolysis [3], converting the zymogen plasminogen to the active serine protease plasmin, which degrades the fibrin network of thrombi and blood clots. tPA is rapidly inactivated by endogenous plasminogen activators inhibitor-1 (PAI-1) [4] (Fig. 1). Engineering on tPA to reduce its inhibition by PAI-1 without compromising its thrombolytic effect is a continuous effort [5]. Tenecteplase (TNK-tPA) is a newer generation of tPA variant showing slower inhibition by PAI-1 [6]. Extensive studies to understand the molecular interactions between tPA and PAI-1 have been carried out [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], however, the precise details at atomic resolution remain unknown. We report the crystal structure of tPA·PAI-1 complex here. The methods required to achieve these data include: (1) recombinant expression and purification of a PAI-1 variant (14-1B) containing four mutations (N150H, K154T, Q319L, and M354I), and a tPA serine protease domain (tPA-SPD) variant with three mutations (C122A, N173Q, and S195A, in the chymotrypsin numbering) [19]; (2) formation of a tPA-SPD·PAI-1 Michaëlis complex in vitro [19]; and (3) solving the three-dimensional structure for this complex by X-ray crystallography [deposited in the PDB database as 5BRR]. The data explain the specificity of PAI-1 for tPA and uPA [19], [20], and provide structural basis to design newer generation of PAI-1-resistant tPA variants as thrombolytic agents [19].

Macrocyclic inhibitors targeting the prime site of the fibrinolytic serine protease plasmin

Design and synthesis of potent and selective macrocyclic thrombin inhibitors

Structural Elements That Govern the Substrate Specificity of the Clot-dissolving Enzyme Plasmin

Mechanism-Based Macrocyclic Inhibitors of Serine Proteases

Structural Principles In The Development Of Cyclic Peptidic Enzyme Inhibitors

Distinctive Binding Modes and Inhibitory Mechanisms of Two Peptidic Inhibitors of Urokinase-Type Plasminogen Activator with Isomeric P1 Residues.

Design of Specific Serine Protease Inhibitors Based on A Versatile Peptide Scaffold: Conversion of A Urokinase Inhibitor to A Plasma Kallikrein Inhibitor

Structural Basis of Specific Inhibition of Tissue-Type Plasminogen Activator by Plasminogen Activators Inhibitor-1

Structural Insight into Inactivation of Plasminogen Activator Inhibitor-1 by A Small-Molecule Antagonist

Crystal Structure of the Michaelis Complex Between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1

P1 and P2' site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor.

Bicyclic Peptide Inhibitor of Urokinase‐Type Plasminogen Activator: Mode of Action

Probing nanosecond motions of plasminogen activator inhibitor-1 by time-resolved fluorescence anisotropy.

Elucidation of the Contribution of Active Site and Exosite Interactions to Affinity and Specificity of Peptidylic Serine Protease Inhibitors Using Non-Natural Arginine Analogs.

Aptameric hirudins as selective and reversible EXosite-ACTive site (EXACT) inhibitors

A dual target of Plasmepsin IX and X: Unveiling the atomistic superiority of a core chemical scaffold in malaria therapy

3-Amino-4-sulfonylpyridinone acetamide and related pyridothiadiazine thrombin inhibitors

Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition

Structural Basis of Specificity of a Peptidyl Urokinase Inhibitor, Upain-1

Design of a Novel Plasminogen Activator Based on the Structure of Hirudin.

Synthesis and Biological Evaluation of Menthol-Based Derivatives As Inhibitors of Plasminogen Activator Inhibitor-1 (PAI-1)